Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Cazzaniga, Marina E.; Torri, Valter; Riva, Francesca; Porcu, Luca; Cicchiello, Federica; Capici, Serena; Cortinovis, Diego; Digiacomo, Nunzio; Bidoli, Paolo
• Is Part Of: Tumori. Volume 103:Issue 1(2017)
• Page Start: 4
• Page End: 8
• Publication Date: 2017-01
• Subjects: Breast cancer -- Capecitabine -- Elderly -- Metronomic chemotherapy -- Vinorelbine; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000543
• Languages: English
• ISSNs: 0300-8916

Abstract

Purpose: Elderly patients with metastatic breast cancer are expected to derive similar benefits from chemotherapy as younger patients, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effective and well tolerated in patients with metastatic breast cancer. This analysis determined the efficacy and safety of the metronomic combination of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patients aged ≥70 years. Methods: Eighteen of the 32 patients enrolled in VICTOR-1 were aged ≥70 years. Objective response and clinical benefit rates were calculated and toxicity was determined using the NCI-CTCAE criteria. Results: All patients had at least 1 comorbidity (4 had 2 comorbidities), and 77.7% were taking concomitant medication. Eight patients (44%) had received ≥1 chemotherapy regimens for metastatic disease and most (78%) had ≥2 metastatic sites. Grade 1-2 adverse events occurred in 45.8% of cycles, whereas the incidence of grade 3 and grade 4 events was very low (1.5% and 0.7%, respectively). Median time to progression was 10.5 months (range 1-40). The objective response rate was 33% and the clinical benefit rate was 67%. Conclusions: The all-oral metronomic combination of vinorelbine and capecitabine had an acceptable efficacy profile and appears to be better tolerated than standard treatment schedules in elderly metastatic breast cancer patients (age ≥70 years).